<DOC>
	<DOCNO>NCT02997358</DOCNO>
	<brief_summary>The objective LMS04 study well define treatment strategy patient metastatic leiomyosarcoma ( uterine soft tissue ) , well identify best first line therapeutic option patient . LMS04 test new strategy first line therapy LMS sarcoma compare reference therapy ( 6 cycle doxorubicin alone ) : interest association trabectedin doxorubicin first line treatment follow trabectedin alone non-progressive patient 6 cycle association trabectedin doxorubicin ( LMS02 design ) . LMS04 first phase III randomize study specifically dedicate soft tissue leiomyosarcoma first line metastatic disease . It plan compare new doxorubicin combination ( include trabectedin ) encourage result follow trabectedin maintenance therapy non-progressive patient doxorubicin alone . Prospective ancillary translational study attempt define profile patient could benefit new chemotherapy exploratory way . The validation new first line option specific LMS , identify clinical factor characterize aggressiveness responsiveness treatment aim important spirit personalize medicine rare deadly disease .</brief_summary>
	<brief_title>Study Comparing Efficacy Doxorubicin With Trabectedin Followed Trabectedin Versus Doxorubicine Patients With Leiomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>1 . Patients must histologically confirm diagnosis metastatic relapse unresectable uterine soft tissue leiomyosarcoma , review reference center ( among RREPS network ) , previously untreated chemotherapy , available Formalin Fixed Paraffin Embedded ( FFPE ) block 2 . At least one measurable lesion accord RECIST V 1.1 criterion . Target could previously irradiate field progressive biopsy positive inclusion . 3 . Age ≥ 18 year old 4 . ECOG performance status &lt; 2 ( Appendix 4 ) 5 . Adequate haematological , liver cardiac function : Neutrophil count ≥ 1500/mm3 Platelets ≥ 100 000/mm3 Serum creatinin &lt; 1.5 x Upper Limit Normal Value ( UNL ) Serum bilirubin ≤1 x ULN ALT , AST ≤ 2.5 x ULN Alcaline phosphatases ≤ 1.5 x ULN Cardiac ultrasound and/or normal isotopic ventriculography : Shortening Fraction ( SF ) &gt; 30 % , Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % 6 . Creatinin phosphokinase ( CPK ) ≤ 2.5 x ULN 7 . Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day prior inclusion . Both male WOCBP sexually active use effective birth control method inclusion ( WOCBP ) treatment initiation ( male ) 6 month follow last dose study drug . 8 . Signed write informed consent form 9 . Patient affiliate social security regimen beneficiary 1 . All histological type uterine sarcoma soft tissue sarcomas 2 . Any contraindication use trabectedin and/or doxorubicin ( cardiac , renal , hepatic , know hypersensitivity… ) 3 . Patient already enrol another therapeutic trial involve investigational substance , substance take previous 4 week . 4 . Medical history progressive psychiatric disorder 5 . History another type cancer complete remission 3 year prior study entry ( except cutaneous basal cell carcinoma situ cervical epithelioma ) , and/or required chemotherapy treatment time . 6 . Known cerebral metastasis 7 . History allograft autograft 8 . Active viral hepatitis B C know human immunodeficiency virus ( HIV ) infection uncontrolled infection 9 . Pregnant woman nurse mother 10 . Patient guardianship deprive liberty judicial administrative decision condition ( e.g. , psychological instability , geographical location , social reason , etc . ) , judgment Investigator , may affect patient 's ability understand sign inform consent fully comply study visit , treatment , procedure , requirement schedule protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>